Yosemite Builds Cancer Breakthroughs | Tech News

Yosemite Venture Partners is rewriting oncology’s playbook—building startups from scratch using university research and philanthropic grants, now raising $350M for its second fund. With interest rates low and pharma giants flush with cash post-patent cliffs, mega-deals are exploding—like Eli Lilly’s $7B Kelonia buyout. Breakthroughs are accelerating: one firm’s KRAS-targeting drug doubled pancreatic cancer survival rates in a year, while Yosemite explores radical new tactics like induced proximity and noninvasive histotripsy for liver and pancreatic tumors. They’re even tackling p53, mutated in nearly all cancers. Yes, setbacks happen—science is messy—but AI is speeding up discovery, and founders must stay nimble as pharma priorities shift. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/61e1fe483d23cff9